UA124450C2 - Спосіб індукції відновлення серця або міокарда або поліпшення функції вказаного серця або міокарда пацієнта - Google Patents

Спосіб індукції відновлення серця або міокарда або поліпшення функції вказаного серця або міокарда пацієнта Download PDF

Info

Publication number
UA124450C2
UA124450C2 UAA201706834A UAA201706834A UA124450C2 UA 124450 C2 UA124450 C2 UA 124450C2 UA A201706834 A UAA201706834 A UA A201706834A UA A201706834 A UAA201706834 A UA A201706834A UA 124450 C2 UA124450 C2 UA 124450C2
Authority
UA
Ukraine
Prior art keywords
samkki
cells
tissue
protein
nucleic acid
Prior art date
Application number
UAA201706834A
Other languages
English (en)
Ukrainian (uk)
Inventor
Марк С. Пен
Мет'ю Кідровскі
Метью Кидровски
Маріца Майорґа
Марица МАЙОРГА
Original Assignee
Самма Хелт
Нортіст Оґайо Медікал Юніверсіті
Нортист Огайо Медикал Юниверсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Самма Хелт, Нортіст Оґайо Медікал Юніверсіті, Нортист Огайо Медикал Юниверсити filed Critical Самма Хелт
Publication of UA124450C2 publication Critical patent/UA124450C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11017—Ca2+/Calmodulin-dependent protein kinase (2.7.11.17)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
UAA201706834A 2014-12-01 2015-12-01 Спосіб індукції відновлення серця або міокарда або поліпшення функції вказаного серця або міокарда пацієнта UA124450C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462086026P 2014-12-01 2014-12-01
PCT/US2015/063118 WO2016089826A1 (en) 2014-12-01 2015-12-01 Camkk1 as a novel regenerative therapeutic

Publications (1)

Publication Number Publication Date
UA124450C2 true UA124450C2 (uk) 2021-09-22

Family

ID=56092307

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201706834A UA124450C2 (uk) 2014-12-01 2015-12-01 Спосіб індукції відновлення серця або міокарда або поліпшення функції вказаного серця або міокарда пацієнта

Country Status (12)

Country Link
US (2) US11273208B2 (cg-RX-API-DMAC7.html)
EP (2) EP3940068A1 (cg-RX-API-DMAC7.html)
JP (2) JP6893873B2 (cg-RX-API-DMAC7.html)
KR (3) KR102236843B1 (cg-RX-API-DMAC7.html)
AU (1) AU2015355188B2 (cg-RX-API-DMAC7.html)
CA (1) CA3007055C (cg-RX-API-DMAC7.html)
CL (1) CL2017001390A1 (cg-RX-API-DMAC7.html)
CR (1) CR20170301A (cg-RX-API-DMAC7.html)
IL (2) IL252612B (cg-RX-API-DMAC7.html)
RU (1) RU2017122817A (cg-RX-API-DMAC7.html)
UA (1) UA124450C2 (cg-RX-API-DMAC7.html)
WO (1) WO2016089826A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016089826A1 (en) 2014-12-01 2016-06-09 Summa Health Camkk1 as a novel regenerative therapeutic
EP3781182A4 (en) 2018-04-18 2021-11-17 Summa Health COMPOSITIONS AND METHODS OF TREATMENT OF ISCHEMIA AND CARDIOMYOPATHIA

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6426206B1 (en) * 2000-11-13 2002-07-30 Pe Corporation (Ny) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
WO2002072115A2 (en) 2001-03-09 2002-09-19 Board Of Regents, The University Of Texas System Vectors, compositions and methods for treating a vascular disorder
US7776564B2 (en) 2004-04-30 2010-08-17 Five Prime Therapeutics, Inc. Stromal cell-derived factor-1 polypeptides, polynucleotides, modulators thereof and methods of use
US7764995B2 (en) * 2004-06-07 2010-07-27 Cardiac Pacemakers, Inc. Method and apparatus to modulate cellular regeneration post myocardial infarct
US8173118B2 (en) * 2004-07-30 2012-05-08 Mayo Foundation For Medical Education And Research Compositions consisting essentially of TGF-β, BMP-2 FGF-4, leukemia inhibitory factor, IGF-1, IL-6 and H-α-thrombin
CN101103101B (zh) 2004-09-24 2012-10-10 成血管细胞系统公司 增强间充质前体细胞（mpc）的增生和/或存活的方法
US20090246179A1 (en) 2008-02-11 2009-10-01 The Cleveland Clinic Foundation Method of treating myocardial injury
EP2687219A1 (en) * 2012-07-18 2014-01-22 Universität Duisburg-Essen Use of preparations comprising exosomes derived from mesenchymal stem cells (MSCs) in the prevention and therapy of inflammatory conditions
EP3039124A1 (en) * 2013-08-29 2016-07-06 Stempeutics Research Private Limited Stromal cells derived conditioned medium, method of obtaining said conditioned medium compositions, formulations and applications thereof
WO2016089826A1 (en) * 2014-12-01 2016-06-09 Summa Health Camkk1 as a novel regenerative therapeutic
HK1246180A1 (zh) 2014-12-31 2018-09-07 Celgene Corporation 使用自然杀伤细胞治疗血液病症、实体瘤或感染性疾病的方法

Also Published As

Publication number Publication date
JP2021098717A (ja) 2021-07-01
EP3227441B1 (en) 2021-06-30
WO2016089826A1 (en) 2016-06-09
EP3227441A1 (en) 2017-10-11
US20170340712A1 (en) 2017-11-30
KR20210010662A (ko) 2021-01-27
CA3007055A1 (en) 2016-06-09
CA3007055C (en) 2023-08-01
IL252612B (en) 2021-07-29
KR102460983B1 (ko) 2022-10-31
JP6893873B2 (ja) 2021-06-23
KR102236843B1 (ko) 2021-04-07
CR20170301A (es) 2018-02-01
EP3940068A1 (en) 2022-01-19
US11273208B2 (en) 2022-03-15
KR20220151004A (ko) 2022-11-11
AU2015355188A1 (en) 2017-07-20
RU2017122817A3 (cg-RX-API-DMAC7.html) 2019-06-11
AU2015355188B2 (en) 2021-08-26
KR20170088988A (ko) 2017-08-02
BR112017011490A2 (pt) 2018-02-27
JP2018502838A (ja) 2018-02-01
CL2017001390A1 (es) 2018-05-11
RU2017122817A (ru) 2019-01-10
IL284408B (en) 2022-06-01
KR102610068B1 (ko) 2023-12-06
US20220233653A1 (en) 2022-07-28
IL252612A0 (en) 2017-07-31
EP3227441A4 (en) 2018-08-15
IL284408A (en) 2021-07-29

Similar Documents

Publication Publication Date Title
CN103263439B (zh) Cd34干细胞相关方法和组合物
US10980841B2 (en) Methods and compositions for in vivo induction of pancreatic beta cell formation
JP5795670B2 (ja) 循環系細胞におけるｐｉｍ−１活性を操作するための組成物および方法
KR101220516B1 (ko) 항－ｍｄｍ２를 발현하는 인간 성체줄기세포 및 그의 용도
US11472859B2 (en) Method and composition for treating neuronal hyper-excitabtiity
EP3202909B1 (en) Cancer specific-splicing ribozyme and use thereof
US20220233653A1 (en) Camkk1 as a novel regenerative therapeutic
KR101500804B1 (ko) Ａｉｍｐ２ 유전자의 스플라이싱 변이체 특이적인 트랜스-스플라이싱 활성을 갖는 핵산 분자 및 이를 이용한 폐암 치료용 약학 조성물 및 폐암 진단용 조성물
ES2560012T3 (es) Métodos y composiciones farmacéuticas para el tratamiento de enfermedades autoinmunitarias
BR112017011490B1 (pt) Uso de plasmídeo ou vetor viral, compreendendo um ácido nucleico que codifica camkk1
US20250283080A1 (en) Gene therapy of hippo signaling improves heart function in a clinically relevant model
Vakrou et al. Gene Therapy in Cardiac Disease
US20240026354A1 (en) Suppressing hippo signaling in the stem cell niche promotes skeletal muscle regeneration
WO2024206687A1 (en) Methods and compostions for engineered mitochondrial biogenesis
Fargnoli et al. Cardiovascular Gene & Cell Therapy
Panel 728. In Vivo Functional Selection Using an AAV Library Encoding the Mouse Secretome Identifies Ghrelin as a Powerful Cardioprotective Molecule
Asada et al. Subcellular localization of EBNA1 and oriP that may support the high rate of exogenous gene transfer achieved using the EBV genetic elements
HK1146488B (en) Cd34 stem cell-related methods and compositions
HK1188735B (en) Cd34 stem cell-related methods and compositions